SAGE Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• SAGE Therapeutics Inc SAGE.OQ reported a quarterly adjusted loss of 79 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.70. The mean expectation of sixteen analysts for the quarter was for a loss of 95 cents per share. Wall Street expected results to range from $-1.07 to -80 cents per share.

• Revenue rose 265.8% to $31.66 million from a year ago; analysts expected $16.76 million.

• SAGE Therapeutics Inc's reported EPS for the quarter was a loss of 79 cents​.

• The company reported a quarterly loss of $49.65 million.

• SAGE Therapeutics Inc shares had fallen by 4.6% this quarter and gained 60.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 2.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 14 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for SAGE Therapeutics Inc is $8.50, about 2.4% below its last closing price of $8.70

This summary was machine generated from LSEG data July 30 at 08:36 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)